Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from VYNE Therapeutics ( (VYNE) ).
On July 30, 2025, VYNE Therapeutics announced the topline results of its Phase 2b trial evaluating Repibresib gel in nonsegmental vitiligo. The trial, which involved 177 subjects, did not meet its primary or key secondary endpoints, leading the company to terminate the trial’s extension phase and seek external partners for further development. Despite the setbacks, VYNE observed nominally statistically significant effects in certain secondary and exploratory endpoints and remains committed to its InhiBET™ BET inhibitor platform. The company also reported an estimated $39.6 million in cash and investments as of June 30, 2025, though these figures are preliminary and unaudited.
The most recent analyst rating on (VYNE) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.
Spark’s Take on VYNE Stock
According to Spark, TipRanks’ AI Analyst, VYNE is a Neutral.
VYNE’s overall stock score is primarily impacted by its poor financial performance, marked by significant revenue declines and persistent losses. The technical analysis provides a slightly more positive short-term outlook, but the valuation remains unattractive due to ongoing unprofitability. The absence of earnings call data and notable corporate events limits additional context.
To see Spark’s full report on VYNE stock, click here.
More about VYNE Therapeutics
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. The company utilizes its proprietary BET inhibitors, part of its InhiBET™ platform, to overcome limitations of early generation BET inhibitors by employing alternative routes of administration and enhanced selectivity.
Average Trading Volume: 691,722
Technical Sentiment Signal: Sell
Current Market Cap: $24.16M
Learn more about VYNE stock on TipRanks’ Stock Analysis page.